Trevi Therapeutics Inc (TRVI)

$2.73

-0.1

(-3.53%)

Market is closed - opens 7 PM, 22 May 2024

Performance

  • $2.67
    $2.84
    $2.73
    downward going graph

    2.2%

    Downside

    Day's Volatility :5.99%

    Upside

    3.87%

    downward going graph
  • $0.97
    $4.00
    $2.73
    downward going graph

    64.47%

    Downside

    52 Weeks Volatility :75.75%

    Upside

    31.75%

    downward going graph

Returns

PeriodTrevi Therapeutics IncIndex (Russel 2000)
3 Months
5.0%
0.0%
6 Months
139.47%
0.0%
1 Year
15.68%
0.0%
3 Years
15.68%
-20.1%

Highlights

Market Capitalization
199.3M
Book Value
$1.05
Earnings Per Share (EPS)
-0.34
Wall Street Target Price
7.33
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-24.56%
Return On Equity TTM
-38.57%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-38.1M
Diluted Eps TTM
-0.34
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.43
EPS Estimate Next Year
-0.47
EPS Estimate Current Quarter
-0.09
EPS Estimate Next Quarter
-0.1

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Trevi Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 168.5%

Current $2.73
Target $7.33

Technicals Summary

Sell

Neutral

Buy

Trevi Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Trevi Therapeutics Inc
Trevi Therapeutics Inc
-7.14%
139.47%
15.68%
15.68%
15.68%
Moderna, Inc.
Moderna, Inc.
37.56%
83.82%
13.37%
-12.47%
553.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
10.42%
24.29%
32.26%
98.6%
210.52%
Novo Nordisk A/s
Novo Nordisk A/s
7.9%
30.89%
58.53%
230.87%
458.51%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.52%
25.13%
30.01%
109.26%
156.43%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Trevi Therapeutics Inc
Trevi Therapeutics Inc
NA
NA
NA
-0.43
-0.39
-0.25
NA
1.05
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.46
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.16
29.16
1.46
44.2
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.83
45.83
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.9
28.9
0.53
17.11
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Trevi Therapeutics Inc
Trevi Therapeutics Inc
Buy
$199.3M
15.68%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$54.0B
553.14%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.8B
210.52%
29.16
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$592.1B
458.51%
45.83
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$115.1B
156.43%
28.9
39.46%

Institutional Holdings

  • NEA Management Company, LLC

    16.14%
  • Rubric Capital Management LP

    8.07%
  • Viking Global Investors LP

    6.25%
  • Opaleye Management Inc

    3.60%
  • BlackRock Inc

    3.29%
  • Vanguard Group Inc

    3.27%

Company Information

trevi therapeutics, inc. is a late-stage biopharmaceutical company focused on developing nalbuphine® er for chronic pruritic conditions. pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions. the company is pursuing several pruritic conditions for clinical development, including its lead indication of prurigo nodularis. prurigo nodularis is a chronic pruritic dermatologic condition characterized by the presence of pruriginous lesions (excoriative/ulcerative papules and nodules) on the skin. there are no approved therapies in the us or eu for this condition. nalbuphine® er is an oral extended release synthetic opioid with a dual mechanism of action, mu receptor antagonist and kappa receptor agonist, both of which have been shown in research to be effective in abolishing itch. because of nalbuphine® er’s unique dual mechanism of action, which has shown efficacy in addressing pruritus in human clinical trials, the company believes nalbuphine® er can

Organization
Trevi Therapeutics Inc
Employees
25
CEO
Ms. Jennifer L. Good
Industry
Pharmaceuticals: Major

FAQs